PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan

breast neoplasms, breast cancer, neoplasm metastasis, trastuzumab-deruxtecan,, human epidermal growth factor receptor 2 positive breast cancer,, human epidermal growth factor receptor 2 low breast cancer,, human epidermal growth factor receptor 2 ultralow breast cancer,, observational